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Abstract
Drug trials in children engage with many ethical issues, from drug-related safety concerns to communication 
with patients and parents, and recruitment and informed consent procedures. This paper addresses the field of 
neuromuscular disorders where the possibility of genetic, mutation-specific treatments, has added new 
complexity. Not only must trial design address issues of equity of access, but researchers must also think 
through the implications of adopting a personalised medicine approach, which requires a precise molecular 
diagnosis, in addition to other implications of developing orphan drugs.
It is against this background of change and complexity that the Project Ethics Council (PEC) was established 
within the TREAT-NMD EU Network of Excellence. The PEC is a high level advisory group that draws upon the 
expertise of its interdisciplinary membership which includes clinicians, lawyers, scientists, parents, 
representatives of patient organisations, social scientists and ethicists. In this paper we describe the 
establishment and terms of reference of the PEC, give an indication of the range and depth of its work and 
provide some analysis of the kinds of complex questions encountered. The paper describes how the PEC has 
responded to substantive ethical issues raised within the TREAT-NMD consortium and how it has provided a 
wider resource for any concerned parent, patient, or clinician to ask a question of ethical concern. Issues raised 
range from science related ethical issues, issues related to hereditary neuromuscular diseases and the new 
therapeutic approaches and questions concerning patients rights in the context of patient registries and bio-
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banks. We conclude by recommending the PEC as a model for similar research contexts in rare diseases.
Introduction
In EU countries a rare disease (RD) is any disease affecting fewer than 5 people in 10,000 12 which translates to 
approximately 425,000 people throughout the EU’s 27 member countries. (www.eucerd.eu and Orphanet 
database www.orpha.net). More than 80% of these diseases are caused by genetic defects. Screening for early 
diagnosis, followed by suitable care, can improve quality of life and life expectancy. Due to the limited interest 
of pharmaceutical industry in developing and marketing products, the EU and national governments have 
prioritised the development of “orphan drugs” for patients with rare diseases. Of the 7,000 rare diseases 
collected in the Online Mendelian Inheritance in Man (OMIM) database (http://www.ncbi.nlm.nih.gov/omim) only 
3,000 genes are known, despite the fact that medical genetics has clearly shown that a prerequisite to 
approaching diagnosis and cure for a RD is to identify the causative mutated gene.
As joint effort will maximise the success and reduce the cost of developing therapies for RDs, it is therefore 
crucial to co-operate within a national and supranational context and this has been recognised via the formation 
of a novel, co-operative initiative by the EU, Canada and the USA, the International Rare Diseases Research 
Consortium (IRDiRC) (IRDiRC, http://ec.europa.eu/research/health/medical-research/rare-
diseases/irdirc_en.html).
The objective of the IRDiRC is to deliver diagnostic tests for most RDs and 200 new therapies for RD patients by 
2020.
Among RDs, neuromuscular diseases (NMDs) are a major research focus. There are a total of 250,000 patients 
in Europe with an estimated NMD frequency of 150-200 per 100,000 34 . NMDs have gained such attention for a 
number of reasons including: i) relatively high frequency of NMDs, thought to be around 3% of all RDs; ii) 
progressive course and devastating impact on the quality of life; iii) elevated mortality often at an early age; iv) 
very high costs in terms of social and health care.
For these reasons RDs and in particular NMDs are considered pivotal for the EU in the field of translational 
research as evidenced by a raft of important goals and initiatives also related to RDs registries, biobanks, 
repositories, site for public consultations and to address the search for excellenct laboratories for the genetic 
diagnoisis, novel trials and care of the disease (http://www.rdtf.org/testor/cgi-bin/OTmain.php; 
http://www.orpha.net/; http://www.eurordis.org/; 
http://asso.orpha.net/RDPlatform/upload/file/SummaryReportRDPlatf03Dec09.pdf).
The challenge of tackling the problem of RDs involves the co-ordination at international level of strategies 
operating on different fronts including: the creation of a common care pathway; research on diagnostics; 
establishment of standards of care; collation of patient data through disease registries; and a co-ordinated 
international network of contact with communication between patients, clinicians, scientists and industry, on 
the premise that joint effort will maximise success and reduce costs.
NMDs can be caused by mutations in hundreds of different genes and the rarity and severity of NMDs varies, 
but they invariably lead to serious impairment and loss of autonomy. Although there is a history of clinical trials 
dating back to the 1970s, it is only during the last decade that the first clinical trials for therapies for genetic 
disease in humans finally arrived 567891011121314.
TREAT-NMD is a Network of Excellence founded by the EU within FP6 (www.treat-nmd.eu). It was designed to 
provide exactly the joined-up network described above. TREAT-NMD aims to advance diagnosis and care and 
develop new treatments for the benefit of patients and families, working closely with scientists, healthcare 
professionals, pharmaceutical companies and patient groups around the world. TREAT-NMD either directly, 
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through its work or indirectly, through supporting various satellite projects on RDs, has succeeded in initiating 
or supporting initiatives on diagnosis, standards of care, patient registries, operating procedures and models, 
clinical trial sites, patient communication and outcome measures.
Work on a wide set of issues across such complex terrain will encounter numerous ethical issues and TREAT-
NMD established a Project Ethics Council (PEC), a multidisciplinary group comprised of clinicians, scientists, 
ethicists, legal academics, parents of patients and representatives of parent and patient organisations, in order 
to respond to such issues. The PEC was established as a high level, multidisciplinary advisory group able to 
respond to ethical questions arising from within the network, and provide a strategic steer on ethical issues for 
the Governing Board. It was also recognised that the PEC needed to be outward facing and accessible to the 
whole of the TREAT-NMD network, from those engaged in translational work to family members and patients. As 
the PEC established itself as a well-formed group operating to clear and mutually agreed terms of reference it 
also widened its remit by being accessible to anyone with an interest in NMDs, rather than just to TREAT-NMD 
members. The TREAT-NMD website therefore became an invaluable resource, providing an access point for 
individuals or organisations to pose a question and as a place where results of the PEC’s deliberations could be 
publicly posted (see http://www.treat-nmd.eu/resources/ethics/pec/questions-received/).
This paper aims at reporting the PEC activities within TREAT-NMD and would be a point of reference for others 
seeking to establish a similar PEC model. In addition to extolling a model of good ethical governance we draw 
attention to the kinds of question raised in the PEC. We believe these are exemplars of common types of ethical 
concern across the wider context of RDs. By drawing attention to these concerns we emphasise the necessity, 
within complex clinical research programmes, to provide the resources and expertise to address ethical issues 
directly and substantively. An important aspect in the added value of the PEC is its diverse membership of 
stakeholders from the NMD field, which allows differing perspectives on a problem in a way that speaks 
authentically to the ethical concerns of NMD patients and families.
Establishing an Ethics Council
The PEC was constituted as a high-level advisory group and although there is considerable expertise shared 
across the members of the PEC it was never envisaged that the PEC would be the source of formal or technical 
guidance on points of law, regulation and governance for the project. The PEC is rather a forum for discussion 
and debate concerning emerging ethical issues and a source of “reflective wisdom” for those posing particular 
questions. The underpinning principles of the PEC, in keeping with a number of contemporary bioethics 
approaches sought to establish a group that was inclusive, democratic and deliberative. The source of the PEC’s 
reflective wisdom therefore stemmed in part from members who are bioethicists and academic lawyers used to 
bringing intellectual analysis to ethical problems, but also from the empirical wisdom of clinicians, scientists, 
parents of children with NMDs and from individuals with careers spanning scientific research and work with 
patient organisations. The PEC’s deliberations produced written responses to questions and other papers made 
available on the TREAT-NMD web site.
The PEC quite quickly adopted a deliberative reflexive approach as its method for considering the ethical issues 
brought before it. Although some may consider this version of an ethics council to be a luxury within the tight 
budget lines of a funded project we found that the PEC could operate highly effectively and very economically 
by making use of simple technology such as the TREAT-NMD intranet and a closed email list, with email 
exchanges and conference calling proving very effective for discussion and deliberation.
Terms of reference
A key issue for the PEC was to create terms of reference that were neither too restrictive nor too permissive, yet 
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captured the key functions of the Council. Rather than adopting a policing function the PEC placed itself as 
responsive to issues as they were raised by anyone within and outside the network.
Perhaps the most substantive ethical issue dealt with within the terms of reference concerned the question of 
confidentiality and here it was agreed that priority ought to be given to openness, meaning that the business of 
the PEC could be openly discussed outside of the PEC unless there was explicit agreement that an issue of 
particular sensitivity was required to be treated in confidence. It was also agreed that PEC members should take 
appropriate care to ensure that any public statements, oral and written presentations on behalf of the PEC 
would be made in the spirit of the PEC’s terms of reference and clearly distinguished from any statements 
members made in a personal capacity. Thus, the terms of reference provided some rules of thumb for its remit 
but allowed for flexibility and the potential for an evolving role within TREAT-NMD. From the very outset it was 
clear that the PEC was to be used as a sounding-board on a wide range of ethical issues covering all aspects of 
the TREAT-NMD network. Over time it became clear that substantive discussion within the PEC was driven in 
two ways, one was by questions posed by non-PEC members and the other was by issues brought to the table 
by PEC members, often acting as conduits for concerns and questions raised by the wider NMD community with 
an interest in advancing the cause of neuromuscular disease care and treatment.
On establishment the work of the Council was viewed as somewhat experimental. Professional experience of 
the members meant terms of reference and procedures for working were soon agreed. However, setting up a 
dedicated, consultative question and service for empirical ethics within a distributed research network was 
novel to most TREAT-NMD members, including the PEC and the decision to work in a reflexive manner 
developed as the PEC established its position. Instituting formal metrics for the PEC’s effectiveness was not 
therefore seen as compatible with such exploratory methodology. That the PEC’s work was seen as helpful, 
constructive and effective is shown by the fact that the Council was consulted regularly on ethical matters and 
was recommended by word of mouth throughout the network. There were also requests from colleagues for the 
PEC to provide additional resources, for example with a publicly available online guide to stem cell treatment 
and cord blood banking (http://www.treat-nmd.eu/sma/clinical-research/stem-cell-tourism/).
Issues
There was a shared common starting point, with which all PEC members agreed, that since NMDs cause a great 
deal of suffering in children (and their families) there is a moral imperative to advance new therapies. This is a 
basic ethical tenet of the TREAT-NMD PEC. It did not however lead PEC members to see all medical research as 
equally necessary, to underestimate the side-effects of treatments, or to support clinical trials uncritically. PEC 
members also agreed that NMD patients have a right that appropriate clinical trials happen which might lead to 
an improvement of their situation.
The TREAT-NMD PEC did not operate within a vacuum but rather against a background of need and growing 
frustration that the fragmentation of translational research on rare disease was resulting in delays that were 
directly detrimental to patients. Patient organisations, some of which pre-date the establishment TREAT-NMD by 
several decades, had already done much to organise themselves, to galvanise interest in RD research and to 
become informed and effective lobbyists 15 . The PEC therefore entered the scene when there was an existing 
organised and complex community of interest. It is apparent from the questions received by the PEC that a 
major preoccupation of the community was clinical trials: when, where, how, and for whom?
In the following section we outline some of the central concerns brought to the PEC for its consideration. Table I 
reports on some of the questions that have been posed to the PEC during its 5 years of activity.
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It is hoped that by reporting the issues and questions that came to the PEC together with the PEC’s responses 
will provide a general picture of the major common concerns related to NMDs and to RDs more generally.
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Table I. Selection of questions posed to the PEC during its 5 years of activity
Issue Submitted by Responses
Relationships with 
industry: How can 
the network protect 
its own interests at 
the same time as 
managing multiple 
relationships with 
companies who may 
be competitors?
Clinician Fruitful relationships with industry should not be jeopardised by 
adopting either a too restrictive approach or by a failure to 
safeguard the genuine interests of industry partners. There is a 
need to be open and honest with industry, noting the need for 
transparency without compromising commercially sensitive 
information.Patient registries should be open to access by 
industry partners and researchers and the Steering Committee 
for the registries ought to act as an intermediary to ensure 
ethical access to and use of data. 
See http://www.treat-nmd.eu/resources/ethics/pec/questions-
received/#1
Steriods in clinical 
trials:
Steroids are 
accepted as 
standard treatment 
for DMD but steroids 
are also recognised 
as a confounding 
factor in assessing 
efficacy of new 
molecules. Is it 
ethical to have trials 
where the boys are 
not on steroids?
Clinician Since steroid use has become an international standard therapy 
it would be wrong to withdraw a beneficial treatment for 
research purposes. However not all patients have been exposed 
to steroids and therefore this information ought to be collated 
on the patient registries so as to be available for investigators 
of clinical trials. 
See http://www.treat-nmd.eu/resources/ethics/pec/questions-
received/#2
Carrying patients 
over from one 
trial phase to 
another:
In rare disease 
studies there can be 
a limited number of 
patients available 
for trial 
participation. Is it 
ethical to ask the 
same patients to 
take part in more 
than one phase of a 
trial?
Clinician An adequate response to this question would always be to a 
large extent ‘question specific’, ‘disease specific’, ‘intervention 
specific’, and (always) ‘protocol specific’. The particular features 
of the case will tell whether a patient would have an increased 
risk or any other additional burden. There is a real danger of 
creating a Catch 22 situation where a population qualifies for 
inclusion in research by virtue of having a rare disease but is at 
the same time disqualified from research due to the risk of over 
research. There may also be a further case on what might be 
called social or moral grounds that whilst it may not be 
scientifically necessary to use the same cohort it is fair and 
respectful (e.g. of autonomy) to do so only where there is little 
or no risk. 
See http://www.treat-nmd.eu/resources/ethics/pec/questions-
received/#6
Unproven stem 
cell “treatment”:
What advice should 
be given to a patient 
who is considering 
paying for stem cell 
therapy at a centre 
which claims to be 
able to treat 
muscular dystrophy?
Clinician This is a highly topical and complex issue and one that raises 
questions about patient autonomy, paternalism, global 
governance, hope and hype regarding new biotechnologies. 
There is no question that patients, or the parents of young 
patients are potential consumers within a globalised market. 
However, the ethics of the market place can not be the ethics of 
the clinic and the provider of “goods and services” does not 
have a fiduciary duty to protect the interests and welfare of the 
patient in the same way that their clinician does.
A key basis of autonomy is knowledge: It is a necessary 
condition of an autonomous choice that parents/patients are 
able to judge the current state of knowledge. Using an 
intervention where the risks are unknown or not made known, 
and without the evidence for benefit makes it impossible to 
make an informed choice. This is not informed consent but 
rather blind faith. 
See http://www.treat-nmd.eu/resources/ethics/pec/questions-
received/#7
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Issue Submitted by Responses
Guaranteeing a 
place on a clinical 
trial:
Is it possible for a 
patient to guarantee 
a place on a clinical 
trial by paying to 
take part?
Parent/relative of 
patient
The very idea of buying a place on a clinical trial suggests a 
complete misunderstanding about the purposes of a trial and an 
unrealistic expectation about its outcome. A trial is the 
therapeutic testing of a potential treatment for humans; it is not 
a treatment or a cure.
Trials are not treatment; they are designed to test for toxicity 
and side effects and/or to demonstrate whether the drug will 
have the desired effect. They allow the collection of scientific 
data about a group, not about a single individual.
In addition, according to the European Clinical Trials Directive 
2001/20/EC it is unethical for any clinician or scientist to act in 
such a way. Such actions are also regarded as illegal in many 
countries. See http://www.treat-
nmd.eu/resources/ethics/pec/questions-received/#8
Use of patient 
registries by 
industry:
How much 
information should 
companies be 
required to make 
available to patients 
about the selection 
of trial sites, 
particularly when 
the company has 
used patient 
registries to help 
with selection?
Patient 
organisation/parent
The PEC endorses the need for open and transparent 
communication between those accessing patient data via the 
registries and patient organisations but does not endorse the 
imposition of restrictive conditions which might prove to be 
counter-productive for the global registry in its relations with 
industry and researchers. The PEC does not agree that there is 
a right for patients to be involved in a clinical trial although it 
strongly endorses the right for clinical trials to happen in the 
most efficient and timely manner. In the interests of fairness 
and equity there should be effort to build the capacity for 
research to take place in every partner country. 
See http://www.treat-nmd.eu/resources/ethics/pec/questions-
received/#9
N=1 trials: 
Is it ethical to offer 
personalised 
therapies to 
individual patients, 
before clinical trials 
of the therapy have 
taken place?
Scientist There is currently no proof that long term treatment with the 
therapy in question – antisense oligonucleotides to induce exon 
skipping – is effective and safe as placebo-controlled trials have 
not yet been conducted. The placebo effect can not be 
discounted and in addition not much is known about longer 
term tolerability and toxicity of these compounds, especially in 
children and adolescents. N = 1 trials are not trials in the 
correct sense of the word. Rather they are the administration of 
potentially harmful substances to a patient in the (possibly 
unjustified) hope that it might help, but without evidence that 
there are reasonable chances that it will. There would be a 
serious risk of setting the entire field back should anything go 
wrong.
The requests for exon skipping treatment for individual patients 
arise from therapeutic misconception and everyone in the field 
has a responsibility to prevent raising false hope and unrealistic 
expectations. Obviously, by agreeing to conduct trials in single 
patients, clinicians only increase misconception and also – 
should exon skipping fail to work as hoped – increase the sense 
of loss and disappointment. 
See http://www.duchenne.nl/1214_artaartsmaNMDn=1
Patient 
representation:
How should the 
patient voice be 
represented within 
TREAT- NMD 
management and 
governance 
structure?
Patient organisation There are two aspects to this question – the constitution of 
TREAT-NMD and its structure. There must be an executive 
committee that is fit for purpose as well as much wider 
mechanisms for facilitating the patient voice throughout TREAT-
NMD. It is critical that TREAT-NMD develops a structure that is 
synergistic with the aims and goals of patients, which must 
include a mechanism to collect, focused views and opinions. On 
the matter of ensuring that the patient voice is encouraged and 
facilitated throughout the Alliance then the PEC would 
encourage the questioner (UPPMD) to provide TREAT-NMD with 
advice and support regarding the good practices and 
approaches that have proven successful in the past. 
See http://www.treat-nmd.eu/resources/ethics/questions-
received/#10
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Trial data sharing and timeliness of clinical trials
TREAT-NMD took as its initial focus two of the commonest forms of NMD in childhood, Spinal Muscular Atrophy 
(SMA) and Duchenne Muscular Dystrophy (DMD). Both are severe, chronic diseases following a relentless 
progressive course characterised by wheelchair and ventilator reliance, thus giving parents an acute awareness 
of the time factor in developing new therapies. It has become well established from other RDs that early 
treatment of progressive disease is more effective 16 .
Several members of the PEC with connections to patient organisations expressed concern that a significant 
hindrance to clinical trial development was the delayed publication of trial results in peer reviewed journals. 
Such complaints are not merely expressions of frustration but supported by evidence which has shown the 
critical connection between the public reporting of trial results and the speed at which new trials are developed. 
171819 . A contributing factor to this information bottleneck is the fact that by far the majority of RD trials are 
sponsored by pharmaceutical companies who, as investors, are naturally cautious about issues of data privacy 
and intellectual property 20 . These issues, together with the timing required for getting a trial approved by 
regulatory authorities, may delay the release of data into the public domain via peer reviewed journals. 
Furthermore, trials can produce large amounts of data, which takes time to collate and analyse. The challenge 
of analysis can also be complicated by the fact that many participants in RD trials are children affected with 
chronic diseases, which increases the complexity of interpreting the outcome 2122 .
Notwithstanding these problems there remain important ethical and practical imperatives in RDs. Clinical trials 
in RDs always involve a limited (and sometimes very limited) number of patients, which can mean offering 
novel drugs in personalised, mutation specific, experimental treatments. Due to the chronic, progressive nature 
of DMD and SMA and other NMDs trials should be long enough to be able to show clinical amelioration 
measured by clinical outcome measures and clinical endpoints 2324 . This is why it is highly desirable that trial 
outcome results are available to other researchers as quickly as possible, in order to inform further work and to 
minimize wasted efforts 25 .
There is therefore a need to promote rapid publication of data from clinical trials in RDs, but also to facilitate 
debate around clinical trial results in order to inform new research strategies.
These imperatives will require a culture change both in the attitudes of pharma and the approaches adopted by 
the academic community. Ideally trial data should be published through the peer review system under which 
academic journals operate, in preference to the current phenomena of trial results often being solely reported 
on pharma’s own websites or in press releases, under their own editorial scrutiny. However there are also 
problems with the very system we recommend, peer reviewed academic journals can take a very long time to 
review and publish a paper. Journals reporting on clinical trials should adopt a common and comprehensive 
system of fast-track review and publishing of trial data. Publishers and scientists should also discuss the 
possibility of new systems to promote timely debate, for example dedicated journals, quick publication, open 
access and parallel commentaries.
To speed up publications dealing with clinical trials in rare disease and also to facilitate debate around such 
results requires a step-change in how trial data is made accessible. In effect this would require journals to 
adopt, for example, a different category of publication and to review and publish clinical trial data on a discrete 
track from other academic submissions.
Broader issues on communication around clinical trials
A related point raised at the PEC by parents and patients concerns the perceived lack of openness of pharma 
8PLOS Currents Muscular Dystrophy
with investigators and participants. In many cases trial results are not communicated or at best only aggregate 
results are released to clinicians and to patient organisations who have helped to fund the research or to set up 
a particular clinical trial (www.clinicaltrials.gov). This widespread concern is often expressed in terms of the 
right of those who have a direct interest in gaining access to timely, clear and appropriately detailed 
information about trial results including individual results where this is appropriate. This point is not new but 
has probably not been supported by the underpinning ethical arguments that have been elaborated in support 
of the related rights of research participants. There is wide international agreement that participation in clinical 
trials should be founded on adequately informed consent. The PEC’s perspective on this issue is that the 
principle of informed participation should be extended to a right to information after participation, since this is a 
reasonable extension of the principle of respect for autonomy which is implicit within informed consent 262721
28 .
Some of those who raised this concern with the PEC asked whether the TREAT-NMD network could bring some 
leverage to bear on pharma who were seeking to access TREAT-NMD’s Global Patient Registry with an intention 
of running a clinical trial. While such stringent measures have strong moral support the PEC reflected that there 
was a risk that applying pressure on pharma might be counter productive and that much more could be gained 
by fostering a collegiate and collaborative approach between stakeholders, with clear voluntary agreements to 
conform to the required ethical standards, as other organisations have done (see Eurordis, www.eurordis.org), 
without first resort to mandatory formal agreements.
Compared to common diseases, there exists general agreement that RDs require dedicated regulatory issues 
for orphan drug designation and trial design (www.eurordis.org). Within the PEC it emerged that the role of 
patient associations and advocacy groups is fundamental as a bridge of communication between patients and 
pharma. Patient associations may be involved in trial design and even be signatories of trial contract 
agreements. Their role should serve to improve dialogue and communication between pharma, patients and 
their families, contributing to a better understanding of research and a higher quality of informed consent 29 .
Overcoming barriers to the organisation of clinical trials: registries
Though SMA and DMD are among the more frequently occurring RDs, patients are dispersed across the world, 
which makes it difficult to organise a clinical trial. RDs are much less likely to benefit from research and 
healthcare development processes, which are designed with common diseases in mind. Yet in the interests of 
justice people with rare disease should be given the same opportunity to benefit from health research and 
treatments as those people with common disorders.
Prior to TREAT-NMD, patient organisations often in collaboration with academic centres, had made significant 
progress in developing and maintaining disease registries with a view to providing feasibility data for clinical 
trials. However, the effort was often fragmented and in order to facilitate accelerated research and 
development for RD data needs to be concentrated and standardised. Patient registries are crucial to achieving 
this. Patient recruitment through registries for RD clinical trials also raises particular ethical issues requiring 
good governance, oversight and audit of the registry 30 .
TREAT-NMD’s contribution has been to draw these separate initiatives together into a global disease registry 
with a validated and standardised approach to data collection, including a record of gene mutations which has 
become vital data in the current era of personalised, mutation specific therapies 3031 . The PEC has proved an 
invaluable resource to the Global Registry Oversight Committee, the body responsible for the governance and 
strategic management of the global registry. In addition to some PEC members having dual membership on the 
Oversight Committee the whole of the PEC has been available as a sounding-board for ethical issues arising out 
of the establishment and running of the global registry. Both the PEC and the Oversight Committee drew upon 
the excellent resources created by Eurordis (http://www.eurordis.org/) giving practical guidance on the creation 
9PLOS Currents Muscular Dystrophy
and maintenance of patient registries as well as advice on the ethical and legal governance of patient data 3233
.
However it is clear that, despite the growing body of expertise in this area, there is a need to reflect upon and 
where necessary revise governance arrangements and remain responsive to the concerns of parents and 
patients when, in an act of trust they place their data and their hopes in the hands of others. A reflection of 
some of the anxieties patients and their families have in these contexts is reflected in one question that seems 
to be a recurrent theme in this context, namely that of ownership, of the registry, of the data, and by 
implication control over its use. Although the issue is comprehensively discussed in the literature and published 
guidelines (http://www.ukbiobank.ac.uk/docs/EGF20082_000.pdf) 3435 , it is clear that part of the duty of care 
owed to registry participants is to offer open reassurance, to be responsive to queries, and to ensure, 
particularly in the initial informed consent process, that such matters are dealt with sensitively and honestly. As 
a guarantee that the privacy related rules are met, all registries should have a specific ethics committee, which 
monitors the flow of data into and out of the registry.
On the theme of good communication the PEC also supported the Global Registry in its efforts to find a clear 
and fair way of communicating with registry participants. The PEC strongly advised the separation of the role of 
the registry from that of trial co-ordinators to avoid the registry being seen as a recruiting agency. It was 
suggested that all registry participants should receive updates on the activities of the registry, but that more 
detailed information about specific clinical trials should only be issued to registry participants who met the 
inclusion criteria for the particular study; with a further option for patients to be able to opt out of “information 
only” letters (templates for these letters are available at www-treat-nmd.eu). Since the Global registry only 
contains anonymised data, the responsibility to determine the final form of communication with participants 
falls to participating national registries. At every point however the PEC was concerned with supporting the 
autonomy and rights of patients to have accurate, detailed and current information.
Relationships with pharmaceutical industry
The establishment of the Global registry is one of the contexts in which discussion of the ethical issues related 
to collaboration with pharmaceutical companies has arisen. The PEC reflected on the view endorsed widely 
across TREAT-NMD that mutually beneficial relationships with industry should not be jeopardised by adopting 
too restrictive an approach to the genuine interests of industry to develop novel therapies. However this was 
balanced by the necessity to respect the wider rights and interests of patients in the ethical management of 
their data. It was recognised that here is a need to be open and honest with industry, to adopt procedural 
transparency without compromising commercially sensitive information but with an expectation that there is an 
open information flow between industry, clinicians and patients. The fact that a mutual co-operation between 
patients and industry is necessary should not result in an ethical approach dictated by a form of “prisoner’s 
dilemma”, where both parties need the co-operation of the other in order to maximise self interest, but do so in 
an atmosphere of mistrust and lack of communication. A more desirable model morally, is one based upon 
mutual respect and understanding for which effective communication is a prerequisite. The broad principles 
offered by the PEC to guide relations with industry are summarised in Table 2, the PEC membership and desired 
qualities/ experiences are listed in Table 3.
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Table 2. The Principles offered by the PEC to guide relations with industry
The broad ethical principles identified by the PEC in the context of patient registries and 
relationships with industry
1. Consent – any collation and use of patient data should be premised upon the provision of high quality 
information either directly to the patient/family or to the registry ‘owner’ e.g. Patient organisation.
2. All use of data should conform to the principles of informed consent
3. In order to maximise best use of patient data e.g. to support the development of further research, relations 
with industry ought to be conducted on the basis of open access: making data available to all parties who 
satisfy the oversight committee requirements and , transparency about who is interested in the data and for 
what purposes (in dialogue with industry partners as to what is reasonable in terms of commercial 
confidentiality)
4. Independent advice/scrutiny should be available to patients / patient organisations on the implications of 
granting access for industry to patient data.
5. Confidentiality- respecting the interests of industry on matters of commercial sensitivity where such 
measure can be reasonably justified and do not conflict with point 6.
6. Any arrangements/ partnerships with industry should be least restrictive of individual rights of patient 
participants.
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Table 3. PEC membership and desired qualities/ experience
Since the PEC was not an executive committee it was open to members who were qualified by experience 
and were able to declare no conflict of interest.
Chair • Philosopher and bioethicist with experience of research ethics at 
national and international level.
Vice Chair • Parent, senior member of parent/patient organisation.
Professional members • Senior Clinicians with a clinical/research interest in NMDs, 
Genetics/Bio-scientists actively researching NMDs and potential 
therapy. 
• Academic lawyer with an interest in the ethical and legal 
aspects of children, Bioethicist.
• Social scientist. 
• Parent with professional experience of regulatory affairs and 
industry.
Lay members • Parents involved in patient/parent organisations.
Membership was drawn from Northern, Southern and Eastern Europe.
Personalised medicine and mutation specific trials: ensuring genetic molecular 
diagnosis
An important piece of data required by the Global registry pro-forma is the recording of the patient’s genetic 
diagnosis. The need for disease specific mutations is with an eye to the potential benefit from personalised 
medicine such as exon skipping or premature stop codon drugs for DMD, in which an accurate genetic diagnosis 
is essential 30 . Accurate detection in large genes with high allele heterogeneity is complex and requires 
specific expertise and equipment. This raises questions regarding the economic aspects of molecular testing as 
well as further ethical concerns if the aspiration of global treatment is to be realised.
The premise that all people with neuromuscular disorders (and other RDs) have a right to treatment and thus a 
right that appropriate clinical trials happen was the starting point for the PEC’s opinion. However, diagnostic 
facilities are not equally available in Europe which makes the development of diagnostic capacity, which will in 
turn support the development of clinical trials, a priority.
Two projects related to TREAT-NMD should help to facilitate this. The FP7- funded NMD-Chip project 
(http://www.nmd-chip.eu/) has developed new high throughput tools to improve the speed and accuracy of the 
diagnostic tests while reducing costs. From this project two major questions were brought to the attention of the 
PEC, namely integrity issues regarding use of DNA reference material for validation of the new tool for 
molecular diagnosis of NMDs, and how to deal with incidental findings of mutations not related to the original 
reason to perform the DNA diagnosis. The BIO-NMD project (http://www.bio-nmd.eu/) is aiming to discover 
novel, disease-specific, biomarkers with a view to improving diagnostics at lower costs. In addition TREAT-NMD 
and EUROGENTEST have jointly published guidelines for the genetic diagnosis of DMD, the most common 
muscular dystrophy affecting children 36. The ethics and governance structures of these projects have both 
benefitted from access to the TREAT-NMD PEC.
Due to the rarity of NMDs, larger clinical trials often involve multiple centres in multiple countries. However, 
these multicentre trials are hampered by the fact that care standards differ for different countries. The TREAT-
NMD related CARE-NMD project aims to address this, with a special focus on optimising care in Eastern 
European countries (http://en.care-nmd.eu/).
The potential availability of therapies for DMD in the near future raised discussions in the PEC about the need to 
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reassess neonatal screening. The Wilson and Jungner criteria for screening state that screening should be 
limited to diseases for which a treatment is available 37 , which is not (yet) the case for DMD. However, recently 
the US neonatal screening results have been published providing answers on that but also raising ethical 
questions 3839 . Based on that, PEC members have argued further that the Wilson and Jungner approach rests 
upon the principle of the child’s best interests. Thus a case could be made to introduce screening for DMD now 
for reasons that include a recognition of the impact of the ‘diagnostic odyssey’ where diagnosis is not confirmed 
for, on average, 2 years after the first concerns are raised. Parents have claimed that early diagnosis would 
have allowed them to be better parents thus furthering the interests of the child. A second and perhaps more 
direct consideration takes into account the potential benefit from early use of steroids in prolonging ambulation 
and improving respiratory function 40 .
The child’s view: involving children in decision making around trial participation
The ethics of clinical research are based on several known guidelines in which the principles of autonomy, 
beneficence, non-maleficence, and fairness remain constant 3541 .
How such principles are honoured can be open to interpretation and when children are the subjects of clinical 
trials these principles become more complicated, indeed some legal guidance precludes the child’s consent to a 
clinical trial presuming the children’s lack of autonomy and inherent vulnerability.
For children under 16 years of age parental/guardian consent is a requirement. Several strands of discussion at 
the PEC dealt with related issues of consent and children’s participation in research.
Decisions about trial participation are taken by the parents or adults legally responsible for the child and 
guidelines for the conduct of research in clinical trials generally do not recognise children’s autonomy. Some 
guidelines explicitly recommend that assent to participation in trials should be sought from children (CIOMS42
and Helsinki43 ) and others that the child should not be involved if they object or appear to object 44 . However, 
there is no legal obligation for investigators to actually seek a child’s assent and few guidelines on how one 
might go about doing so 454647 . In addition, it is unclear how widespread the practice of seeking assent is.
Conclusions
New therapies in rare NMDs raised specific ethical issues that are not fully covered by commonly used ethical 
guidelines. An appropriate ethical clarification of these issues needs an institutional capacity to identify, see and 
evaluate them in their concrete contexts. To do this needs the experiences of families who are acquainted with 
the disease. Therefore, ethical expertise needs to be organised not only inter-disciplinarily (as is common in 
research ethics committees) but also include experiential knowledge through the inclusion of patient 
representatives.
The TREAT-NMD PEC addressed some of the main issues related to rare NMDs care, diagnosis, treatments and 
ethics, possibly representing a suitable model for addressing similar issues in the context of other Rare 
Diseases.
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